Description: IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Home Page: www.intelgenx.com
6420 Abrams
Montreal,
QC
H4S 1Y2
Canada
Phone:
514 331 7440
Officers
| Name | Title |
|---|---|
| Dr. Horst G. Zerbe Ph.D. | Chairman, CEO & Chairman of Scientific Advisory Board |
| Mr. André Godin C.A., CPA, CA, CPA | Pres & CFO |
| Mr. Tommy Kenny J.D., L.L.B., M.Sc. | VP of Intellectual Property & Legal Affairs and Gen. Counsel |
| Ms. Nadine Paiement | Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp |
| Stephen Kilmer | Investor Relations Officer |
| Ms. Ingrid Zerbe | Corp. Sec. |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.9023 |
| Price-to-Sales TTM: | 17.2776 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |